Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13276241 | 0.86 | ADRB3 (0.36) | ALDH1A1ADRB3CYP3A4CYP3A5TSHR | |
| SCHEMBL3029558 | 0.79 | KCNA5 (0.33) | ALDH1A1MEN1KMT2AMAPK1KCNA5 | |
| SCHEMBL13276042 | 0.76 | CYP1A2 (0.43) | ALDH1A1MAPK1KDM4E | |
| SCHEMBL2101549 | 0.74 | HTR4 (0.60) | — | |
| SCHEMBL3962428 | 0.74 | HTR4 (0.48) | — | |
| SCHEMBL13276125 | 0.73 | PDE4A (0.39) | ALDH1A1KDM4E | |
| SCHEMBL3029553 | 0.69 | ADRB3 (0.32) | ALDH1A1KMT2AKCNA5ADRB3 | |
| SCHEMBL13276306 | 0.64 | HTR4 (0.32) | ALDH1A1 | |
| SCHEMBL13276242 | 0.63 | CRY1 (0.46) | ALDH1A1KDM4ETSHR | |
| SCHEMBL13276282 | 0.61 | CYP1A2 (0.46) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264779-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264779-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | ALDH1A1 2540/4885MEN1 1587/4885KMT2A 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.